FDA and Manufacturers Ponder Biosimilars Pathway - Follow-on versions of complex biologics require extensive expertise. - BioPharm International


FDA and Manufacturers Ponder Biosimilars Pathway
Follow-on versions of complex biologics require extensive expertise.

BioPharm International
Volume 24, Issue 7, pp. 12-14


A key challenge for FDA is to define interchangeability testing requirements and whether clinical switching studies will be required. Manufacturers want products to qualify as interchangeable because the first follow-on biologic so deemed by FDA enjoys a year of market exclusivity, during which FDA may not approve another similar interchangeable product. The designation also is important for acceptance by patients and healthcare professionals, and for possible substitution by pharmacists and prescribers.

Gordon Johnson, vice-president of the Generic Pharmaceutical Association, noted at the DIA/FDLI meeting that switching studies are not required for innovator manufacturers to document comparability following postapproval changes. Gillian Woollett, chief scientist at the law firm Engel & Novitt, added during the conference that documenting comparability to the innovator inherently supports a finding on interchangeability. Innovator biologics experience batch-to-batch variability over the product's life time, Woollett observed, and that kind of variability should be accepted in biosimilars.

Yet, innovators maintain that clinical studies in multiple populations with different risk–benefit profiles are necessary to document that there are no greater risks of safety problems or efficacy differences with product switching. Amgen Vice-President Anthony Mire-Sluis maintained that head-to-head studies are needed to compare immunogenicity between reference and follow-on biotechnology products, and that different assays can yield different rates of immunogenicity. He also wants product labels to state explicitly the approved indications of a therapy and whether a biosimilar is interchangeable for that use.

The potential for product naming and coding to drive coverage and reimbursement generates heated debate on those topics. Innovator firms maintain that biosimilars should have unique names to distinguish them from reference products, an issue that BPCI failed to address. Different names can ensure traceability of adverse events, reduce confusion about interchangeability, and prevent dispensing errors.

Biosimilar advocates prefer names linked to a reference product to "make clear to prescribers and patients that the products are related," explained attorney Erika Lietzan of Covington & Burling during the conference. Some physicians propose unique names only for noninterchangeable biosimilars. European Union guidance calls for biosimilars to have different names, but most relate to innovator products. FDA officials may seek to promote safety with names that differentiate similar versions of a drug.

Product coding raises related issues. Innovators want biosimilars to have their own reimbursement codes, while biosimilars makers want the same code for all drugs in the same class. A dozen human growth hormone products have the same Medicare reimbursement code and thus receive the same rate of reimbursement, explained attorney Laura Loeb of King & Spalding. But even without interchangeability status and common codes, Loeb predicts that it will be difficult for more expensive reference products to maintain market share. Formulary committees and state Medicaid programs, she points out, can drive prescribing through formulary placement, higher copays, prior authorization, and requiring-step therapy procedures for reference products. "The burden will be on the reference product to prove superiority to the biosimilar," Loeb observed, "not the other way around."

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here